Adel K El-Naggar
Overview
Explore the profile of Adel K El-Naggar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
345
Citations
13611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoff C, de Sousa L, Bonini F, Lago E, Wang K, Siqueira J, et al.
Cancer Med
. 2025 Mar;
14(5):e70663.
PMID: 40025676
Background: Adenoid cystic carcinoma (ACC) with NOTCH-activating mutations presents a clinical challenge due to its poor prognosis. NOTCH inhibitors have emerged as a potential therapy for ACC patients with NOTCH...
2.
Jawert F, Fehr A, Persson M, El-Naggar A, Stenman G, Andersson M
Head Neck
. 2025 Feb;
PMID: 39996285
Background: Adenoid cystic carcinoma (ACC) is an aggressive therapy-resistant head and neck cancer with a high frequency of local recurrences and distant metastases. Activation of the MYB gene, encoding an...
3.
Shirima C, Bleotu C, Spandidos D, El-Naggar A, Gradisteanu Pircalabioru G, Michalopoulos I
Oncol Rep
. 2024 Sep;
52(4).
PMID: 39219259
Head and neck squamous cell carcinomas (HNSCCs), a heterogeneous group of cancers that arise from the mucosal epithelia cells in the head and neck areas, present great challenges in diagnosis,...
4.
Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers
Karpinets T, Mitani Y, Chang C, Wu X, Song X, Flores I, et al.
Sci Rep
. 2024 Jul;
14(1):16300.
PMID: 39009605
Adenoid cystic carcinoma (ACC) is a rare, usually slow-growing yet aggressive head and neck malignancy. Despite its clinical significance, our understanding of the cellular evolution and microenvironment in ACC remains...
5.
McDaniel J, Morrissey R, Dibra D, Patel L, Xiong S, Zhang Y, et al.
Cancer Res Commun
. 2024 Jul;
4(8):1991-2007.
PMID: 38994678
Significance: Our findings implicate NR5A2 as a novel mediator of mutant p53 transcriptional activity in breast cancer. NR5A2 may be an important therapeutic target in hard-to-treat breast cancers such as...
6.
Hoff C, Dal Lago E, Siqueira J, de Sousa L, El-Naggar A, Rodon Ahnert J, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300633.
PMID: 38579194
First use of AXL-targeting in adenoid cystic carcinoma (ACC); with positive results, ACC now included in AXL studies.
7.
Klijanienko J, Masliah-Planchon J, Choussy O, Rougier G, Vautrin A, Lesnik M, et al.
Acta Cytol
. 2024 Mar;
68(2):107-120.
PMID: 38437817
Introduction: Poorly differentiated primary sarcomatoid parotid malignancies are extremely rare. These tumors have not been consistently studied by morphology, immunohistochemistry, or molecular techniques. Case Presentation: We report three unusual cases...
8.
Dibra D, Xiong S, Moyer S, El-Naggar A, Qi Y, Su X, et al.
Sci Adv
. 2024 Feb;
10(7):eadk1835.
PMID: 38354236
The tumor suppressor gene is mutated early in most of the patients with triple-negative breast cancer (TNBC). The most frequent alterations are missense mutations that contribute to tumor aggressiveness. Here,...
9.
Siqueira J, Mitani Y, Hoff C, Bonini F, De Sousa L, Marques-Piubelli M, et al.
Mod Pathol
. 2023 Nov;
37(1):100371.
PMID: 38015043
B7-H4 (VTCN1), a member of the B7 family, is overexpressed in several types of cancer. Here we investigated the pattern of expression of B7-H4 in salivary gland carcinomas (SGC) and...
10.
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, et al.
JAMA Oncol
. 2023 Sep;
9(11):1565-1573.
PMID: 37768670
Importance: Patients with locally advanced non-human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti-epidermal growth factor receptor (EGFR) antibody improves overall...